Dermatology
Articles filed under Dermatology.
Ustekinumab for plaque psoriasis approved by FDA
Ustekinumab is a monoclonal antibody that targets IL-12 and IL-23, it is approved for the treatment of plaque psoriasis. Read the latest recommendations on its use.
Efalizumab (Raptiva) for plaque psoriasis. EMEA recommends withdrawal of its marketing authorization, FDA issues public health advisory
Raptiva and progressive multifocal leukoencephalopathy : EMEA recommends withdrawal of marketing authorization and FDA recommends monitoring patients.
Potential new indication of beta blockers: improve wound healing
A recent article in PLoS Medicine shows that epinephrine impairs wound healing and proposes beta blockers as a potential medication. Stress-Mediated Increases in Systemic and Local Epinephrine Impair Skin Wound Healing: Potential New Indication for Beta Blockers Raja K. Sivamani1, Christine E. Pullar1¤, Catherine G. Manabat-Hidalgo1, David M. Rocke2, Richard C. Carlsen3, David G. Greenhalgh4,5,
Review of retapamulin (Altargo), a new topical antibiotic for skin infections
Information from Health Canada about retapaumulin (Altargo), a pleuromutilin antibiotic for the treatment of impetigo and skin infections. On March 19, 2008, Health Canada issued a Notice of Compliance to GlaxoSmithKline Inc. for the drug product AltargoTM. AltargoTM contains the medicinal ingredient retapamulin which is an antibiotic. AltargoTM is indicated for use in adult and
Efalizumab (Raptiva) and progressive multifocal leukoencephalopathy (PML). New safety information
This is duplicated text of a letter from EMD Serono Canada Inc to health care professionals, available at Health Canada . Dear Health Care Professional, EMD Serono Canada Inc., in collaboration with Health Canada, would like to inform you of important new safety information regarding the risk of serious infections, including progressive multifocal leukoencephalopathy (PML),